{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:11:02Z","timestamp":1793923862924,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/S024093\/1"],"award-info":[{"award-number":["EP\/S024093\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274507"],"award-info":[{"award-number":["U54CA274507"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Math Biol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care. Prior AT protocols apply drug treatment when the tumor is within a specific size window, typically determined by the initial tumor size. However, this approach may be sub-optimal as it does not account for variation in tumor dynamics between patients, resulting in significant heterogeneity in patient outcomes. Mathematical modeling and analysis have been proposed to optimize adaptive protocols, but they do not account for clinical restrictions, most notably the discrete time intervals between the clinical appointments where a patient\u2019s tumor burden is measured and their treatment schedule is re-evaluated. We present a general framework for deriving optimal treatment protocols that account for these discrete time intervals, and derive optimal schedules for several models to avoid model-specific personalization. We identify a trade-off between the frequency of patient monitoring and the time to progression attainable, and propose an AT protocol that determines drug dosing based on a patient-specific threshold for tumor size. Finally, we identify a subset of patients with qualitatively different dynamics that instead require a novel AT protocol based on a threshold that changes over the course of treatment.<\/jats:p>","DOI":"10.1007\/s11538-025-01525-y","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:20:05Z","timestamp":1757344805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-115X","authenticated-orcid":false,"given":"Kit","family":"Gallagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian A. R.","family":"Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R. A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"1525_CR1","doi-asserted-by":"crossref","unstructured":"Adhyam M, Gupta AK (2012) A review on the clinical utility of PSA in cancer prostate. Indian Journal of Surgical Oncology, 3(2):120\u2013129","DOI":"10.1007\/s13193-012-0142-6"},{"issue":"9","key":"1525_CR2","first-page":"772","volume":"28","author":"KH Allison","year":"2014","unstructured":"Allison KH, Sledge GW (2014) Heterogeneity and cancer. Oncology 28(9):772\u2013772","journal-title":"Oncology"},{"key":"1525_CR3","doi-asserted-by":"crossref","unstructured":"Bacevic K, Noble R, Soffar A, Ammar OW, Boszonyik B, Prieto S, Vincent C, Hochberg ME, Krasinska L, Fisher D (2017) Spatial competition constrains resistance to targeted cancer therapy. Nature Communications, 8(1)","DOI":"10.1038\/s41467-017-01516-1"},{"issue":"21","key":"1525_CR4","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.3390\/cancers14215319","volume":"14","author":"R Brady-Nicholls","year":"2022","unstructured":"Brady-Nicholls R, Enderling H (2022) Range-bounded adaptive therapy in metastatic prostate cancer. Cancers 14(21):5319","journal-title":"Cancers"},{"issue":"2","key":"1525_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cncr.21989","volume":"107","author":"N Bruchovsky","year":"2006","unstructured":"Bruchovsky N, Klotz L, Crook J, Malone S, Ludgate C, Morris WJ, Gleave ME, Goldenberg SL (2006) Final results of the canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer. Cancer 107(2):389\u2013395","journal-title":"Cancer"},{"key":"1525_CR6","doi-asserted-by":"crossref","unstructured":"Crook JM, O\u2019Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367(10):895\u2013903","DOI":"10.1056\/NEJMoa1201546"},{"key":"1525_CR7","doi-asserted-by":"crossref","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl\u00e9chon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","DOI":"10.1056\/NEJMoa1014618"},{"key":"1525_CR8","doi-asserted-by":"crossref","unstructured":"Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, Ruiz E, Martinez G, Minton S, Gillies RJ, Gatenby RA (2016) Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Science Translational Medicine, 8(327)","DOI":"10.1126\/scitranslmed.aad7842"},{"issue":"11","key":"1525_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-23-2040","volume":"84","author":"K Gallagher","year":"2024","unstructured":"Gallagher K, Strobl MA, Park DS, Spoendlin FC, Gatenby RA, Maini PK, Anderson AR (2024) Mathematical model-driven deep learning enables personalized adaptive therapy. Can Res 84(11):1929\u20131941","journal-title":"Can Res"},{"key":"1525_CR10","doi-asserted-by":"crossref","unstructured":"Gallagher K, Strobl MAR, Maini PK, Anderson ARA (2025) Predicting treatment outcomes from adaptive therapy \u2013 A new mathematical biomarker. BioRxiv","DOI":"10.1101\/2025.04.03.646615"},{"key":"1525_CR11","doi-asserted-by":"crossref","unstructured":"Gallaher J, Masud MA, Eroglu Z, Anderson ARA (2025) Abstract 6242: Adaptive therapy in advanced basal cell carcinoma driven by imaging and mathematical modeling. Can Res 85(8 Supplement 1):6242\u20136242","DOI":"10.1158\/1538-7445.AM2025-6242"},{"issue":"8","key":"1525_CR12","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","volume":"78","author":"JA Gallaher","year":"2018","unstructured":"Gallaher JA, Enriquez-Navas PM, Luddy KA, Gatenby RA, Anderson AR (2018) Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Can Res 78(8):2127\u20132139","journal-title":"Can Res"},{"issue":"11","key":"1525_CR13","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Can Res 69(11):4894\u20134903","journal-title":"Can Res"},{"key":"1525_CR14","doi-asserted-by":"crossref","unstructured":"Gerlinger, M. and Swanton, C. (2010). How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer, 103(8):1139\u20131143","DOI":"10.1038\/sj.bjc.6605912"},{"issue":"12","key":"1525_CR15","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.3390\/cancers12123556","volume":"12","author":"E Hansen","year":"2020","unstructured":"Hansen E, Read AF (2020) Modifying adaptive therapy to enhance competitive suppression. Cancers 12(12):3556","journal-title":"Cancers"},{"issue":"2","key":"1525_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2001110","volume":"15","author":"E Hansen","year":"2017","unstructured":"Hansen E, Woods RJ, Read AF (2017) How to use a chemotherapeutic agent when resistance to it threatens the patient. PLoS Biol 15(2):e2001110","journal-title":"PLoS Biol"},{"key":"1525_CR17","doi-asserted-by":"crossref","unstructured":"Huo X, Kohli M, Finkelstein J (2025) Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram. IOS Press","DOI":"10.3233\/SHTI250070"},{"key":"1525_CR18","doi-asserted-by":"crossref","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314\u20131325","DOI":"10.1056\/NEJMoa1212299"},{"issue":"3","key":"1525_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.6004\/jnccn.2018.7098","volume":"17","author":"JM Jacobs","year":"2019","unstructured":"Jacobs JM, Ream ME, Pensak N, Nisotel LE, Fishbein JN, MacDonald JJ, Buzaglo J, Lennes IT, Safren SA, Pirl WF, Temel JS, Greer JA (2019) Patient experiences with oral chemotherapy: Adherence, symptoms, and quality of life. J Natl Compr Canc Netw 17(3):221\u2013228","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"1525_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/cancers13040823","volume":"13","author":"E Kim","year":"2021","unstructured":"Kim E, Brown JS, Eroglu Z, Anderson AR (2021) Adaptive therapy for metastatic melanoma: Predictions from patient calibrated mathematical models. Cancers 13(4):823","journal-title":"Cancers"},{"issue":"3","key":"1525_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1021\/j150111a004","volume":"14","author":"AJ Lotka","year":"1910","unstructured":"Lotka AJ (1910) Contribution to the theory of periodic reactions. J Phys Chem 14(3):271\u2013274","journal-title":"J Phys Chem"},{"key":"1525_CR22","doi-asserted-by":"crossref","unstructured":"Lu Y, Chu Q, Li Z, Wang M, Gatenby R, Zhang Q (2024) Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer. Briefings in Bioinformatics, 25(2)","DOI":"10.1093\/bib\/bbae071"},{"key":"1525_CR23","doi-asserted-by":"crossref","unstructured":"Moreira A, Bernardo C, Ramos C, Aguiar P, Alves\u00a0da Costa F (2022) National trends in the use of oral chemotherapy over 13 years. Frontiers in Pharmacology, 13","DOI":"10.3389\/fphar.2022.909948"},{"issue":"12","key":"1525_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091262","volume":"14","author":"UA Mukherjee","year":"2024","unstructured":"Mukherjee UA, Hockings H, Counsell N, Patel A, Narayanan P, Wilkinson K, Dhanda H, Robinson K, McNeish I, Anderson ARA, Miller R, Gourley C, Graham T, Lockley M (2024) Study protocol for adaptive chemotherapy for ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer. BMJ Open 14(12):e091262","journal-title":"BMJ Open"},{"issue":"7","key":"1525_CR25","first-page":"1307","volume":"61","author":"L Norton","year":"1977","unstructured":"Norton L, Simon R et al (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61(7):1307\u20131317","journal-title":"Cancer Treat Rep"},{"key":"1525_CR26","doi-asserted-by":"crossref","unstructured":"Robertson-Tessi M, Brown JS, Poole MI, Johnson M, Marusyk A, Gallaher JA, Luddy KA, Whelan CJ, West J, Strobl M, Turati V, Enderling H, Schell MJ, Tan A, Boyle T, Makanji R, Farinhas J, Soliman H, Lemanne D, Gatenby RA, Reed DR, Anderson ARA, Chung CH (2023) Feasibility of an evolutionary tumor board for generating novel personalized therapeutic strategies. MedRxiv","DOI":"10.21203\/rs.3.rs-2485094\/v1"},{"key":"1525_CR27","doi-asserted-by":"crossref","unstructured":"Sabbagh Dit\u00a0Hawasli R, Barton S, Nabhani-Gebara S (2021) Ambulatory chemotherapy: Past, present, and future. Journal of Oncology Pharmacy Practice, 27(4):962\u2013973","DOI":"10.1177\/1078155220985916"},{"key":"1525_CR28","doi-asserted-by":"crossref","unstructured":"Strobl M, Gallaher J, Robertson-Tessi M, West J, Anderson A (2023) Treatment of evolving cancers will require dynamic decision support. Annals of Oncology, 34(10):867\u2013884","DOI":"10.1016\/j.annonc.2023.08.008"},{"issue":"4","key":"1525_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1158\/0008-5472.CAN-20-0806","volume":"81","author":"MA Strobl","year":"2021","unstructured":"Strobl MA, West J, Viossat Y, Damaghi M, Robertson-Tessi M, Brown JS, Gatenby RA, Maini PK, Anderson AR (2021) Turnover modulates the need for a cost of resistance in adaptive therapy. Can Res 81(4):1135\u20131147","journal-title":"Can Res"},{"key":"1525_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-022-00110-x","volume":"2","author":"MAR Strobl","year":"2022","unstructured":"Strobl MAR, Gallaher J, West J, Robertson-Tessi M, Maini PK, Anderson ARA (2022) Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Communications Medicine 2:1\u201318","journal-title":"Communications Medicine"},{"key":"1525_CR31","doi-asserted-by":"crossref","unstructured":"Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug resistance. The Lancet Oncology, 13(4):e178\u2013e185","DOI":"10.1016\/S1470-2045(11)70335-7"},{"issue":"6","key":"1525_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41559-021-01428-w","volume":"5","author":"Y Viossat","year":"2021","unstructured":"Viossat Y, Noble R (2021) A theoretical analysis of tumour containment. Nature Ecology & Evolution 5(6):826\u2013835","journal-title":"Nature Ecology & Evolution"},{"issue":"1","key":"1525_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/icesjms\/3.1.3","volume":"3","author":"V Volterra","year":"1928","unstructured":"Volterra V (1928) Variations and fluctuations of the number of individuals in animal species living together. ICES J Mar Sci 3(1):3\u201351","journal-title":"ICES J Mar Sci"},{"key":"1525_CR34","doi-asserted-by":"crossref","unstructured":"West J, Desai B, Strobl M, Pierik L, Velde RV, Armagost C, Miles R, Robertson-Tessi M, Marusyk A, Anderson ARA (2020) Antifragile therapy. BioRxiv","DOI":"10.1101\/2020.10.08.331678"},{"key":"1525_CR35","doi-asserted-by":"crossref","unstructured":"Zhang J, Cunningham J, Brown J, Gatenby R (2022) Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. eLife, 11","DOI":"10.7554\/eLife.76284"},{"key":"1525_CR36","doi-asserted-by":"crossref","unstructured":"Zhang J, Cunningham JJ, Brown JS, Gatenby RA (2017) Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nature Communications, 8(1)","DOI":"10.1038\/s41467-017-01968-5"}],"container-title":["Bulletin of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-025-01525-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11538-025-01525-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-025-01525-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:18:05Z","timestamp":1758788285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11538-025-01525-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s11538-025-01525-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.01.25325056","asserted-by":"object"}]},"ISSN":["0092-8240","1522-9602"],"issn-type":[{"value":"0092-8240","type":"print"},{"value":"1522-9602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"146"}}